Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NMIL 12 1

Next Previous
Drug Profile

NMIL 12 1

Alternative Names: HemaMax; KPT-1200; NM-IL-12; NMIL12-1; Recombinant-human-interleukin-12 - Neumedicines; Recombinant-interleukin-12 - Neumedicines; rHu-IL12; rHuIL-12 – Neumedicines

Latest Information Update: 28 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neumedicines
  • Class Interleukins; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Interferon gamma stimulants; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants; Tumour necrosis factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute radiation syndrome
  • Phase II Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma
  • No development reported Malignant melanoma; Solid tumours
  • Discontinued Acute myeloid leukaemia; Pancytopenia; Wound infections

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Second-line therapy or greater) in USA (Parenteral)
  • 28 Oct 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Second-line therapy or greater) in USA (Parenteral)
  • 01 Apr 2022 Phase-II clinical trials in Diffuse large B cell lymphoma (Combination therapy) in USA (Parenteral), prior to April 2022 (Libo Pharma pipeline, April 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top